Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives -- Proceeds support advancing Attovia’s lead programs through initial clinical readouts, expanding its pipeline, and ongoing development of the ATTOBODY™ platform -- Financing led by Goldman Sachs...

Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards -- Hubert Chen, accomplished drug developer and pharma executive, joins as Chief Medical Officer -- Industry veterans and leading academic experts joined Attovia’s Clinical and Scientific...

Attovia Announces Second Tranche Closing of $60 Million Series A Financing and Highlights Progress Building a Best-in-Class Pipeline Leveraging the Attobody™ Platform -- Financing supports building immunology and inflammation pipeline, advancing lead programs into the clinic and ongoing development of the Attobody platform -- Attovia’s lead programs include...

Attovia Therapeutics Launches with $60 Million Series A Financing to Unlock Potential of Novel Biparatopic Nanobody Platform Company Formed by Alamar Biosciences and Frazier Life Sciences Attobody™ Platform Generates Small Format Binders for Hard-to-drug Targets FREMONT, Calif. and MENLO PARK, Calif., June 20, 2023 ...